Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers

SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products